| Project Detail |
Immune checkpoint inhibitors have revolutionized cancer therapy, yet the majority of patients do not respond to current treatments, such as PD-1/PD-L1blockade. In non-small cell lung cancer (NSCLC), over 70% of patients experience immune evasion mechanisms that prevent effective immune activation. One such mechanism involves the overexpression of glycans on tumor cells, which can modulate immune responses. In this project, we propose to develop novel bispecific bi-paratopic antibodies that simultaneously target two distinct epitopes of the target. This innovative approach is designed to provide a more comprehensive blockade of immune-suppressive functions by dual engagement of the receptor. Our bispecific antibodies will be engineered and optimized to target different epitopes, enhancing their ability to restore immune function. The project will involve the engineering, structural characterization, and functional validation of the bispecific antibodies, followed by preclinical efficacy studies in NSCLC models. By this approach, these antibodies have the potential to overcome the limitations of existing immunotherapies, offering a new therapeutic option for cancer patients who are resistant to current treatments. In addition to the scientific development, this ERC PoC project is designed to develop a robust commercialization strategy, with the potential for patent filings and engagement with pharmaceutical partners. Our vision is to bring these bispecific antibodies to the clinic, ultimately aiming to improve outcomes for patients with NSCLC and other cancers. |
